DMOAD Makes The Difference

Adequan® Canine (polysulfated glycosaminoglycan) is the only FDA-approved disease-modifying osteoarthritis drug (DMOAD) clinically proven to treat the disease of OA.1

A disease-modifying osteoarthritis drug (DMOAD) acts on the tissues involved in OA to prevent the progression of structural changes.2 Unlike NSAIDs, nutraceuticals or joint supplements that focus primarily on managing the pain associated with OA, Adequan Canine not only provides fast relief but also effectively treats the disease of OA, not just the clinical signs.1

Adequan Canine is the only product proven to inhibit cartilage loss in a dog’s synovial joints and may help to:1

  • Restore joint lubrication
  • Relieve inflammation
  • Renew the building blocks of healthy cartilage

Using the DMOAD Adequan Canine along with other supportive modalities — such as weight control, daily walking and pain management — helps keep dogs moving.

Adequan Canine has been prescribed and relied on by veterinarians for more than 20 years.

Why treat just the signs of canine osteoarthritis when you can proactively treat the disease?

Special diets, supplements and anti-inflammatory drugs can play a part in managing joint disease but none of them specifically address the underlying cartilage deterioration. Once cartilage wears away completely, it can’t be restored so it’s vital to help maintain its use.2 That’s what makes Adequan® Canine (polysulfated glycosaminoglycan) different. It empowers you to proactively treat the disease and not just the signs of canine osteoarthritis.1

Adequan Canine canine joint damage

INDICATIONS Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

How To Use Graph How To Use Graph

The one joint prescription
that works differently.

Adequan® Canine is the only FDA-approved disease-modifying osteoarthritis drug (DMOAD) that inhibits cartilage loss in a dog’s joints.1

The specific mechanism of action of Adequan® in canine joints is not known.1

Discover if Adequan® Canine is the right choice.

Know the early signs of OA.

The first signs of OA often appear as subtle changes in a dog’s behavior. Left unrecognized and untreated, degenerative joint disease can progress to more severe signs that can adversely affect long-term mobility. Some of the early warning signs include:3,4

  • Unusual body positions when resting or sleeping
  • Struggles to get comfortable - frequently changes positions
  • Stiff, slow or shaky when getting up
  • Shifts weight while standing
  • Reluctant to sit, walk or climb stairs
  • Has trouble squatting to eliminate

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Osteoarthritis (OA)
Treating Early With Adequan® Canine (polysulfated glycosaminoglycan)
Video Transcript

Denis J. Marcellin-Little

“We can positively impact osteoarthritis at its early stages by protecting cartilage. For example, with Adequan® Canine, we know that cartilage breakdown can be decreased, the cartilage can be protected early in the course of the disease.

“This has a profound positive impact on dogs because we catch the disease at its early stages. We will have healthier joints for a lifetime.”

Kristin Kirkby Shaw

“There are certain activities that are better and certain ones that are worse. And then there are some products and some treatments that we can start using earlier on in the osteoarthritis disease process that can really potentially change the whole course of the disease, and they’re going to be most effective early on.

“And most specifically I’m talking about Adequan® Canine.”

Julia Tomlinson

“In my practice Adequan® Canine is one of my initial go-to medications for early osteoarthritis. I really feel that we can intervene to try and help the joint health a little bit more than we can with some of the other things available to me.

“And I like to be able to minimize the use of nonsteroidals when we’re early in the disease so that we can use it as maybe a rescue medication and use Adequan® Canine more.”

Bryan T. Torres

“When it comes to something like osteoarthritis, treating it early is the way to go. This is with any disease process, right?

“And so something like Adequan® Canine that we can use early on when we first diagnose osteoarthritis in a patient, and we can do that, then make an impact for a long period of time with them can be highly beneficial.”

Whit Cothern

“We want to have that early discussion about the use of Adequan® Canine, have that out there as one of the therapeutic options, a very important therapeutic option, early in our osteoarthritis management protocols.”

Anne Dagner

“The first thing I tell clients about Adequan® Canine and why it could be right for their dog is that we really want to slow the progression of osteoarthritis. And that’s what the main goal is when we’re using this drug.

“The next thing I talk to them about is that it’s been around, it’s been approved by the FDA so that we know it’s a safe and effective product. So we feel confident when we’re using it in their dog.”

The participants are paid consultants for American Regent Animal Health. The opinions of these consultants may not be representative of American Regent Animal Health.

© 2021, American Regent, Inc.
PP-AC-US-0310 11/2020

Adequan® Canine brand of polysulfated glycosaminoglycan (PSGAG)
INDICATIONS Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.
IMPORTANT SAFETY INFORMATION Adequan® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see Full Prescribing Information.
1. Adequan® Canine Package Insert, Rev 9/2021.
2. 2016 NAVC Proceedings, Osteoarthritis in Dogs and Cats: Novel Therapeutic Advances, M Epstein, DVM, DABVP C/F, CVPP; K Kirkby Shaw, DVM, MS, PhD, DACVS, DACVSMR.
3. Clinician’s Brief, Aug 2013, Canine OA, DA Canapp, DVM, CCRT, CVA, DACVSMR.
4. Face validity of a proposed tool for staging canine osteoarthritis: Canine Osteoarthritis Staging Tool (COAST), T. Cachon, O. Frykman, J.F. Innes, B.D.X. Lascelles, M. Okumura, P. Sousa, F. Staffieri, P.V. Steagall, B. Van Ryssen, COAST Development Group, The Veterinary Journal, 235 (2018) 1-8.

Let’s stay in touch.

Be the first to hear about important news and product information!
First, select the one that best describes you.
Then we'll take you to our sign-up page.

About Us Our Brands